Dr. Kaye has been a practicing physician scientist for over 30 years. He is Vice Chancellor of Academic Affairs at LSU Health Shreveport. It has been a personal goal of his to significantly contribute to the education and development of future physicians, scientists, professors, and researchers. Dr. Kaye’s laboratory has made significant scientific contributions through in vivo, prospective human clinical trials, and retrospective data review research involving anesthesiology airway devices, multimodal pain management, and novel pharmaceuticals. In 2022 he has contributed to 12 books, 44 book chapters, and 144 PubMed articles, all of which include students, residents, and faculty, and involve collaborations from different departments at LSU. Overall, he has published over 1000 PubMed articles and has authored/co-authored over 300 abstracts. Dr. Kaye has mentored hundreds of clinical fellows, residents, and faculty appointments, in addition to hundreds of medical and graduate students. Dr. Edwards received his PhD in the Departments of Neuroscience and Psychiatry at the University of Texas Southwestern Medical Center with support from the National Institute on Drug Abuse (NIDA). Afterwards, he joined the Committee on the Neurobiology of Addictive Disorders at The Scripps Research Institute where he was awarded a K99/R00 Pathway to Independence award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Dr. Edwards joined the Department of Physiology at LSU Health New Orleans in 2013 and is a member of the NIAAA-funded P60 Comprehensive Alcohol-HIV/AIDS Research Center and Alcohol & Drug Abuse Center of Excellence. His preclinical and translational research examines neurobiological interactions between chronic pain and substance use disorders.

• The Opioid Receptor System and Novel Aspects of Opioid Pharmacology1. Making Sense of the Complexities of Opioid Receptor Function: Evolving Appreciation of Opioid Receptor Classification and Basic Characteristics2. Allostery at Opioid Receptors: Modulation with Small Molecule Ligands, Regulator of G-Protein Signaling (RGS) Protein Modulation of Opioid Receptor Signaling as a Potential Target for Pain Management3. Opioid Agonist and Antagonist Pharmacology: Phenylpiperidines, Tramadol, Buprenoprhine, Methadone, and Codeine Derivatives Synthetic Opioid Clinical Considerations4. Pharmacogenomics/Precision Medicine: Opioid-related Interactions and Metabolism Considerations5. Opioid-associated Syndromes and Comorbidities6. Opioid-induced Hyperalgesia7. Drug Facts: Novel Synthetic Opioids Synthetic Opioid Misuse and Pain Management8. Roots of the Opioid Crisis: Description of the Four Waves of the Opioid Epidemic9. Opioids and Risk of Dependency: Neurobiology of Opioid Use Disorder10. Opioids and Risk of Dependency: Responsibilities of Healthcare Workers, Manufacturers, and Pharmacists11. CDC Guidelines for Chronic Pain in the Adult, Including Newer Guidelines Against Co-prescription with Benzodiazepines.12. Commonly Prescribed Opioids and Adjuvants in Acute and Chronic Pain Management13. Clinical Considerations of Commonly Prescribed Medications in Substance Abuse Management (e.g., buprenorphine (how is it prescribed); methadone (concerns over prolonged QT EKG prior to administration; urine drug screens14. The Role of Naltrexone and Novel Preparations for Substance Abuse and Pain Management15. Palliative Care for Cancer and Considerations for Opioid-mediated Suppression of Natural Killer Cells16. Abuse Deterrent Formulations of Opioids and Opioid Vaccines17. Opioid Detoxification Techniques

Dr. Kaye has been a practicing physician scientist for over 30 years. He is Vice Chancellor of Academic Affairs at LSU Health Shreveport. It has been a personal goal of his to significantly contribute to the education and development of future physicians, scientists, professors, and researchers. Dr. Kaye’s laboratory has made significant scientific contributions through in vivo, prospective human clinical trials, and retrospective data review research involving anesthesiology airway devices, multimodal pain management, and novel pharmaceuticals. In 2022 he has contributed to 12 books, 44 book chapters, and 144 PubMed articles, all of which include students, residents, and faculty, and involve collaborations from different departments at LSU. Overall, he has published over 1000 PubMed articles and has authored/co-authored over 300 abstracts. Dr. Kaye has mentored hundreds of clinical fellows, residents, and faculty appointments, in addition to hundreds of medical and graduate students. Dr. Edwards received his PhD in the Departments of Neuroscience and Psychiatry at the University of Texas Southwestern Medical Center with support from the National Institute on Drug Abuse (NIDA). Afterwards, he joined the Committee on the Neurobiology of Addictive Disorders at The Scripps Research Institute where he was awarded a K99/R00 Pathway to Independence award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Dr. Edwards joined the Department of Physiology at LSU Health New Orleans in 2013 and is a member of the NIAAA-funded P60 Comprehensive Alcohol-HIV/AIDS Research Center and Alcohol & Drug Abuse Center of Excellence. His preclinical and translational research examines neurobiological interactions between chronic pain and substance use disorders.

• The Opioid Receptor System and Novel Aspects of Opioid Pharmacology1. Making Sense of the Complexities of Opioid Receptor Function: Evolving Appreciation of Opioid Receptor Classification and Basic Characteristics2. Allostery at Opioid Receptors: Modulation with Small Molecule Ligands, Regulator of G-Protein Signaling (RGS) Protein Modulation of Opioid Receptor Signaling as a Potential Target for Pain Management3. Opioid Agonist and Antagonist Pharmacology: Phenylpiperidines, Tramadol, Buprenoprhine, Methadone, and Codeine Derivatives Synthetic Opioid Clinical Considerations4. Pharmacogenomics/Precision Medicine: Opioid-related Interactions and Metabolism Considerations5. Opioid-associated Syndromes and Comorbidities6. Opioid-induced Hyperalgesia7. Drug Facts: Novel Synthetic Opioids Synthetic Opioid Misuse and Pain Management8. Roots of the Opioid Crisis: Description of the Four Waves of the Opioid Epidemic9. Opioids and Risk of Dependency: Neurobiology of Opioid Use Disorder10. Opioids and Risk of Dependency: Responsibilities of Healthcare Workers, Manufacturers, and Pharmacists11. CDC Guidelines for Chronic Pain in the Adult, Including Newer Guidelines Against Co-prescription with Benzodiazepines.12. Commonly Prescribed Opioids and Adjuvants in Acute and Chronic Pain Management13. Clinical Considerations of Commonly Prescribed Medications in Substance Abuse Management (e.g., buprenorphine (how is it prescribed); methadone (concerns over prolonged QT EKG prior to administration; urine drug screens14. The Role of Naltrexone and Novel Preparations for Substance Abuse and Pain Management15. Palliative Care for Cancer and Considerations for Opioid-mediated Suppression of Natural Killer Cells16. Abuse Deterrent Formulations of Opioids and Opioid Vaccines17. Opioid Detoxification Techniques

Dr. Kaye has been a practicing physician scientist for over 30 years. He is Vice Chancellor of Academic Affairs at LSU Health Shreveport. It has been a personal goal of his to significantly contribute to the education and development of future physicians, scientists, professors, and researchers. Dr. Kaye’s laboratory has made significant scientific contributions through in vivo, prospective human clinical trials, and retrospective data review research involving anesthesiology airway devices, multimodal pain management, and novel pharmaceuticals. In 2022 he has contributed to 12 books, 44 book chapters, and 144 PubMed articles, all of which include students, residents, and faculty, and involve collaborations from different departments at LSU. Overall, he has published over 1000 PubMed articles and has authored/co-authored over 300 abstracts. Dr. Kaye has mentored hundreds of clinical fellows, residents, and faculty appointments, in addition to hundreds of medical and graduate students. Dr. Edwards received his PhD in the Departments of Neuroscience and Psychiatry at the University of Texas Southwestern Medical Center with support from the National Institute on Drug Abuse (NIDA). Afterwards, he joined the Committee on the Neurobiology of Addictive Disorders at The Scripps Research Institute where he was awarded a K99/R00 Pathway to Independence award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Dr. Edwards joined the Department of Physiology at LSU Health New Orleans in 2013 and is a member of the NIAAA-funded P60 Comprehensive Alcohol-HIV/AIDS Research Center and Alcohol & Drug Abuse Center of Excellence. His preclinical and translational research examines neurobiological interactions between chronic pain and substance use disorders.

• The Opioid Receptor System and Novel Aspects of Opioid Pharmacology1. Making Sense of the Complexities of Opioid Receptor Function: Evolving Appreciation of Opioid Receptor Classification and Basic Characteristics2. Allostery at Opioid Receptors: Modulation with Small Molecule Ligands, Regulator of G-Protein Signaling (RGS) Protein Modulation of Opioid Receptor Signaling as a Potential Target for Pain Management3. Opioid Agonist and Antagonist Pharmacology: Phenylpiperidines, Tramadol, Buprenoprhine, Methadone, and Codeine Derivatives Synthetic Opioid Clinical Considerations4. Pharmacogenomics/Precision Medicine: Opioid-related Interactions and Metabolism Considerations5. Opioid-associated Syndromes and Comorbidities6. Opioid-induced Hyperalgesia7. Drug Facts: Novel Synthetic Opioids Synthetic Opioid Misuse and Pain Management8. Roots of the Opioid Crisis: Description of the Four Waves of the Opioid Epidemic9. Opioids and Risk of Dependency: Neurobiology of Opioid Use Disorder10. Opioids and Risk of Dependency: Responsibilities of Healthcare Workers, Manufacturers, and Pharmacists11. CDC Guidelines for Chronic Pain in the Adult, Including Newer Guidelines Against Co-prescription with Benzodiazepines.12. Commonly Prescribed Opioids and Adjuvants in Acute and Chronic Pain Management13. Clinical Considerations of Commonly Prescribed Medications in Substance Abuse Management (e.g., buprenorphine (how is it prescribed); methadone (concerns over prolonged QT EKG prior to administration; urine drug screens14. The Role of Naltrexone and Novel Preparations for Substance Abuse and Pain Management15. Palliative Care for Cancer and Considerations for Opioid-mediated Suppression of Natural Killer Cells16. Abuse Deterrent Formulations of Opioids and Opioid Vaccines17. Opioid Detoxification Techniques